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ABSTRACT 
SLOW RELEASE AND DELIVERY OF ANTISENSE 
OLIGONUCLEOTIDE DRUG BY SELF-ASSEMBLED PEPTIDE 
AMPHIPHILE NANOFIBERS 
Selma Bulut 
M.S. in Materials Science and Nanotechnology 
January, 2012 
Antisense oligonucleotides are short single stranded DNA sequences and 
they are suggested to be used for treatment of several disorders including 
cancer. They could enter the cell and specifically inhibit the target gene, 
however chemical stability, controlled release and intracellular delivery are 
areas that has to be focused on to increase their efficacy. Gels composed of 
nanofibrous peptide network have been previously suggested as carriers for 
controlled delivery of drugs to improve stability and to provide controlled 
release, but have not been used for oligonucleotide delivery. In this work, a 
self-assembled peptide nanofibrous system is formed by mixing a cationic 
peptide amphiphile (PA) with Bcl-2 antisense oligodeoxynucleotide (ODN), 
G3139, through electrostatic interactions. The self-assembly of PA-ODN gel 
was characterized by circular dichroism, rheology, atomic force microscopy 
(AFM) and scanning electron microscopy (SEM). AFM and SEM images 
revealed establishment of the nanofibrous PA-ODN network. Due to the 
iv 
 
electrostatic interactions between PA and ODN, ODN release can be 
controlled by changing PA and ODN concentrations in the PA-ODN gel. 
Cellular delivery of the ODN by PA-ODN nanofiber complex was observed 
by fluorescently labeled ODN molecule. Cells incubated with PA-ODN 
complex had enhanced cellular uptake compared to cells incubated with 
naked ODN. Furthermore, Bcl-2 mRNA amounts were lower in MCF-7 
human breast cancer cells in the presence of PA-ODN complex compared to 
naked ODN and mismatch ODN evidenced by quantitative RT-PCR studies. 
These results suggest that PA molecules can control ODN release, enhance 
cellular uptake and present a novel efficient approach for gene therapy 
studies and oligonucleotide based drug delivery. In follow-up studies, 
increase in the internalization efficacy of ODN by incorporation of bioactive 
sequences, RGDS, to peptide sequence was also shown.      
 
 
 
 
 
 
Keywords: peptide; amphiphile; nanofiber; antisense oligonucleotide; 
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ÖZET 
DNA BAZLI ANTİKANSER İLAÇLARININ NANOFİBERLERLE 
KONTROLLÜ SALIMI VE TAŞINIMI 
Selma Bulut 
Malzeme Bilimi ve Nanoteknoloji Programı, Yüksek Lisans 
Ocak, 2012 
Antisens oligodeoksinükleotitler (ODN) kanser dâhil birçok hastalığın 
tedavisinde kullanılabilen önemli ilaçlardır. Ancak kimyasal dayanıklılık, 
kontrollü salım ve hücre içerisine alım oligonükleotitlerin verimini etkileyen 
önemli faktörlerdir. Nanofibrillerden oluşan üç boyutlu ağsı yapıya sahip jeller 
ilaçların kontrollü salımı ve taşımı amacıyla ilaç dayanıklılığını arttırmak için 
kullanılmıştır, fakat oligonükleotitler için bir çalışma yoktur.  Bu çalışmada, 
programlı toplanabilir peptit nanofiber sistemi, pozitif yüklü amfifilik peptit 
(AP) molekülleri ile Bcl-2 antisens oligodeoksinükleotidi, G3139, karıştırılarak 
elektrostatik etkileşimlerin etkisiyle oluşturuldu. Programlı toplanabilir AP ve 
ODN jeli dairesel dikroism, reoloji, atomik kuvvet mikroskobu (AFM) ve 
taramalı elektron mikroskobu (SEM) kullanılarak karakterize edildi. AFM ve 
SEM görüntüleri jelin nanofiber ağsı yapısını göstermektedir. Jelden ODN 
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salımı katyonik AP‟ler ve anyonik ODN‟ler arasındaki elektrostatik 
etkileşimlere bağlıdır. Çalışmamızda AP ve ODN konsantrasyonları 
değiştirilerek ODN salımı kontrol edildi. Floresan işaretli ODN kullanılarak AP-
ODN kompleksinin hücre içerisine alınımı incelendi. AP-ODN kompleksi 
uygulanan MCF-7 insan meme kanseri hücrelerinin daha fazla floresan sinyali 
verdiği gözlendi. Ayrıca AP-ODN kompleksi ile inkübe edilen MCF-7 
hücrelerinin Bcl-2 mRNA ifadesinin, çıplak halde ODN ve 2-bazı eşleşmeyen 
(mismatch-MM) ODN, 2-bazı eşleşmeyen (mismatch-MM) ODN ve AP 
kompleksi ile inkübe edilen hücrelerdeki mRNA ifadesinden daha fazla azaldığı 
kantitatif RT-PZR yöntemi ile gösterildi. Bu sonuçlar AP moleküllerinin ODN 
salımının kontrolü ve hücre içerisine verimli ODN alımı için kullanılabileceğini 
ve gen terapisinde yeni bir yaklaşım olabileceğini önermektedir. Devam eden 
çalışmalarda, ODN„nin hücre içerisine alımının RGDS biyoaktif dizileriyle 
arttırıldığı gösterildi. 
 
 
 
 
Anahtar Kelimeler: peptit; amfifil; nanofiber; antisens oligonukleotit; 
G3139; Bcl-2; ilaç taşınımı, antikanser ilaç  
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1. INTRODUCTION 
 
1.1 Antisense Oligonucleotide Technology 
Antisense (AS)  oligonucleotides are unmodified or chemically modified 
short, single stranded DNA or RNA sequences that are designed to bind 
specifically to target RNA
1
. Antisense oligonucleotides could be used as 
inhibitors to regulate expression of specific genes to downregulate target 
proteins for treatment of diseases such as cancer, viral infections and 
inflammatory diseases based on complementation of specific oligonucleotide 
to a chosen sequence
2-3
. 
On the basis of the mechanism of action, there are two classes of 
antisense oligonucleotides, the steric-blocker oligonucleotides and the 
RNase H-dependent oligonucleotides. The steric-blocker oligonucleotides 
include methylphosphonates, 2′-O-methyloligoribonucleotides, PNAs 
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(Peptide Nucleic Acid), and morpholino oligonucleotides, which prevent 
protein expression by hybridizing with splice sites or intron regions of RNA 
physically.  
The RNase H-dependent oligonucleotides have RNase H competent 
backbones that are phosphodiesters and phosphorothioates. Phosphodiesters 
and phosphorothioates are oligodeoxynucleotide (ODN) having sequences of 
16 to 29 bases of single stranded DNAs. ODNs are the most common 
antisense oligonucleotides designed to speciﬁcally downregulate targeted 
genes by inhibiting translation of unwanted proteins by blocking the 
ribosomal machinery and/or recruiting endogenous RNase H enzyme
6
. After 
single-stranded ODNs enter the cell cytoplasm, they accumulate in the cell 
nucleus and hybridize with the complementary region in the corresponding 
RNA via Watson-Crick base pairing. DNA/RNA duplex triggers a defense 
mechanism and then RNase H, a ubiquitous enzyme, recognizes the 
oligonucleotide/RNA duplex as a substrate. RNase H cleaves the RNA 
strand and releases the antisense oligonucleotide that is free to bind to other 
targeted RNA molecules. RNase H is also present in the cytosol and cleaves 
DNA/RNA hybrids and down-regulates mRNA expression of specific 
proteins
4-5
(Fig. 1). Phosphorothioates, which contain sulfur in place of 
oxygen in the phosphodiester bond, are the most widely studied 
oligonucleotides. Because of their nuclease stability and relative ease of 
synthesis
1
, the phosphorothioate AS oligonucleotides are currently available 
for many clinical uses
7,8,9-11
. Fomivirsen (Vitravene) is a phosphorothioate 
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antisense oligonucleotide that has been approved by the Food and Drug 
Administration for treatment of cytomegalovirus retinitis
3
. 
 Due to ability to recognize specific target complementary sequences; in 
theory, antisense molecules can be designed to inhibit expression of any 
gene
12
. Use of oligonucleotides as gene expression inhibitors have some 
advantages, such as target specificity and reduced side effects. However, 
because of their rapid degradation by intracellular endonucleases and 
exonucleases, AS oligonucleotides cannot be used effectively as drugs to 
inhibit target gene expression
13-14. To overcome these problems, there are 
ongoing studies to increase the stability of these molecules, such as chemical 
modification. The mostly used chemically modified oligonucleotides are 
methylphosphonates, 2′-O-methyloligoribonucleotides, PNAs, morpholino 
oligonucleotides and phosphorothioates
6
. Chemically modified 
oligonucleotides have improved stability, however, when they are not 
combined with proper delivery agents, they have limited ability to cross the 
cell membrane due to their charge and high molecular weight
15,16
. Thus, 
further developed and more efficient delivery systems are necessary for 
enhanced cellular uptake. To achieve sustained pharmacological activity of 
oligonucleotides, facilitate their delivery and to avoid multiple 
administrations, several release and non-viral delivery systems based on 
biodegradable polymers, lipids and their combination have been suggested 
such as cationic liposomes
17-22
, protamine-containing lipid nanoparticles
23
, 
synthetic biodegradable polymers, nano or microparticles (polylactide-co-
glycolide microparticles)
24-25
, cationic nanoparticles
26
, hydrogels (PLA-b-
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PEG-b-PLA hydrogel)
27
, micelles (polylactide–polyethylene glycol 
copolymers)
28
, fibrous scaffolds (electrospun polyethylene co-vinylacetate), 
polylactic acid
29
) and cationic polymers (polyethylenimine
30
, modified 
PEI/ODN polyplexes
31
,  poly-lysine
32
, cationic facial amphiphiles
33
), and  
polycationic peptide
34
. These non-viral delivery systems are usually 
hydrophilic, positively charged and able to interact with oligonucleotides 
through electrostatic interactions permitting desired molecular design with 
controlled size for specific applications.
35-36 
 
 
 
Figure 1. Representative image of RNase H-dependent antisense 
mechanism (picture adapted with permission from Dean et. al.
5
). 
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  In viral systems, human pathogenic viruses such as retrovirus, 
adenovirus, and baculovirus vectors are used as delivery agents with high 
transfection efficacies. However viral systems have limitations such as 
virally-induced inflammatory responses, immune reactions, finite capsule 
size with low performance in serum and costly process to maintain. As 
delivery agents, non-viral delivery vectors; lipids and/or cationic polymers 
and peptides, constructed with biodegradable materials are preferred over 
viral systems. Non-viral delivery systems permit the molecular design, at 
least in principle, of a vehicle with controlled size and architecture that can 
properly accommodate the desired transgene for a specific application
37-40. 
The non-viral systems mentioned above decrease enzymatic degradation of 
chemically unmodified oligonucleotides and partially increase their cellular 
uptake. However, these systems are generally difficult to use and they show 
extracellular non-specific interactions in vivo, have problems in intracellular 
trafficking to the nucleus and mostly do not work in the serum containing 
media
41
. Furthermore, highly positively charged polymers such as 
polyethylenimine (PEI) cause cellular toxicity
42
. Therefore, new systems are 
needed to improve cellular uptake and reduce side effects.  
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1.2  Use of Peptide Amphiphile Nanofibers in Medicine 
Peptide amphiphiles consist of a hydrophilic and hydrophobic group. 
Hydrophilic peptide headgroup is made up of charged amino acid residues 
such as net negative (aspartic acid (D), glutamic acid (E)), net positive 
(histidine (H), lysine (K), arginine (R)), or a mixture of positive and negative 
residues while hydrophobic tails consist of 3–9 non-polar amino acid 
residues (e.g. glycine (G), alanine (A), valine (V), phenylalanine (F), proline 
(P), isoleucine (I), leucine (L)) or alkyl tail that are composed of 
hydrocarbon chains of 12–16 carbons or mixture of hydrocarbon chain and 
non-polar amino acids
43
. During molecular self-assembly of peptide 
amphiphiles, amino acids could be spontaneously organized into larger well 
ordered nanostructures using non-covalent bonds; hydrophobic interactions, 
electrostatic forces, hydrogen bonding and aromatic interactions
44
. The 
morphology of the final assembled structure depends on the structure of the 
monomer, peptide length and composition of peptide amphiphiles. Peptide 
sequence that carries specific information on their side chains such as 
hydrophilicity, hydrophobicity and chirality and composition of peptide 
amphiphiles such as length of the hydrophobic part determine self assembly 
process. Self Assembly process results in different final nanostructures since 
formation of β-sheet and α-helix secondary structures depend on 
hydrophobic and hydrophilic residues such as the geometry of the polar head 
group and the shape of each molecule
45
. Several self-assembling peptidic 
aggregates have been designed including nanotubes, nanovesicles, nanobelts 
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and nanofibers with hydrophobic tail collapsed inside the core of the 
structure and hydrophilic residues projected on the outside, facing water
46
  
Peptide amphiphiles (PA), which have an alkyl carbon tail linked 
covalently to the N terminal of a peptide sequence named lipopeptides, were 
developed by Hartgerink et al
47
. These PAs are composed of a hydrophobic 
site, a β-sheet forming short peptide sequence, a hydrophilic peptide 
sequence, and a bioactive peptide group. These peptide amphiphiles self 
assemble through weak, noncovalent interactions such as intermolecular 
association of the hydrophobic portions with the help of intermolecular polar 
interactions; electrostatic forces, hydrogen bonding and aromatic 
interactions. 
 PA molecules form highly ordered, one-dimensional cylindrical 
nanostructures through self-assembly. Hydrophobic site of PA molecules, 
composed of a long alkyl chain, induces hydrophobic collapse and remains 
in the interior part of the nanofiber structure while the hydrophilic peptide 
segment with net charge enables solubility in water and presents bioactive 
peptide sequence to the surface of these self-assembled nanostructures
48-49
. 
The β-sheet structures are formed through intermolecular hydrogen bonding 
between peptides, oriented parallel along the axis of the well-defined, one-
dimensional nanoﬁber structures around 8-10 nm in diameter and up to a 
few micrometers in length depending on composition of peptide sequences
47, 
49-51
. Transition of the amphiphilic self-assembly of spherical micelles to 
cylindrical nanofibers is promoted by beta sheet formation with alanine, 
valine, glycine, and leucine residues that drive hydrogen bonding among 
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peptide segments. These self-assembled materials are sensitive to 
environmental changes such as temperature, pH, and ionic strength of the 
solution, as well as the concentration of the monomer
52. Neutralization of the 
charged groups by addition of oppositely charged molecules such as 
biomacromolecules (e.g. DNA, protein, polysaccharides), divalent ions or 
change in pH trigger spontaneous nanofiber assembly of PAs through charge 
screening with the help of hydrogen bond formation. Water absorption by 
the mesh-like network formed by bundles of these nanofibers results in gel 
formation
53-54. Chemical, physical and biological properties of nanofibers 
can be controlled by non-covalent bonds and supramolecular interactions
55.  
Peptide amphiphiles (PA) are promising tools for drug and gene delivery 
systems since they are biocompatible and bioactive. Gels formed by PAs 
have been used for various applications in regenerative medicine as 
extracellular matrix (ECM) – mimicking materials for repairing damaged 
tissues
56
, in cancer studies to kill cancer cells with anti-cancer epitope
57
, and 
in drug and gene delivery to improve stability and transfection efficacy. PA 
gels are comprised of meshwork of nanofibers with biofunctional epitopes 
derived from extracellular matrix proteins to form synthetic matrices that 
mimic natural ECM and have been used in regenerative medicine 
applications; such as angiogenesis induction
58
, neural
59-60
, bone
61
, cartilage 
regeneration
62
 and survival of pancreatic islets
63
. In gene delivery 
applications, PAs that are composed of hydrophobic amino acids or alkyl tail 
and hydrophilic group is functionalized with bioactive sequences and cell 
penetration peptide sequences to facilitate cellular uptake. RGDS sequence 
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derived ECM protein; fibronectin, provides recognition system with integrin 
receptors in cell surfaces. The integrins constitute a family of cell-adhesion 
receptors that simultaneously interact with the proteins in the extracellular 
matrix and the internal constituents of the cell and it is known that 
expression of integrins is increased in cancer cells. By this way, integrins 
provide communication between cell and its environment, allowing the cell 
to respond to its environment and regulate cell morphology, differentiation, 
proliferation, and gene expression
64-65. Cell penetration peptide sequences 
such as, penetratin derived from Antennapediaprotein (AntpHD) and Tat 
derived from human immunodeficiency virus 1(HIV1) trans-activating 
transcriptional activator; enable the intracellular delivery of polar, 
biologically active compounds in vitro and in vivo
65, 66-70
.  
PAs were also functionalized for slow release of proteins such as sonic 
hedgehog (SHH) protein
71
, and to deliver or encapsulate growth factors (e.g. 
bone morphogenetic protein factor-2
72
 and fibroblast growth factor
73
). 
Koutsopoulos and his colleagues used hydrogels of the ac-(RADA)4-CONH2 
peptide monomer for controlled release of functional proteins; insulin, 
trypsin inhibitor, BSA, and IgG through nanofiber
74
. Moreover PA 
nanofibers were employed to deliver and encapsulate hydrophobic drugs 
including pyrene
75
,  doxorubicin
76
, cisplatin
77
, and ellipticine
78
. 
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3.1 Peptide Amphiphiles for Release and Delivery of Antisense 
ODN   
Herein, we evaluate self-assembled nanofiber formation of PA system 
with G3139 oligonucleotide as a slow release and delivery system. We 
demonstrate a new carrier system to deliver G3139 as an antisense 
oligonucleotide drug model. G3139 (Genasense®, Genta Inc., NJ) is a 
chemically modified 18-mer antisense oligodeoxynucleotide (ODN) which 
is modified chemically with phosphorothioate, designed to bind to the first 
six initiation codons of the Bcl-2 mRNA. Heteroduplex of mRNA and ODN 
activates RNase H, which cleaves the mRNA sequence, resulting in the 
degradation of mRNA, thereby inhibiting the production of Bcl-2 protein ( 
Fig. 2)
79-80
. Bcl-2 protein family is crucial for mediating controlled cell death 
and overexpression of Bcl-2 protein leads to accumulation of aged and 
damaged cells resulting in tumor formation. Although Bcl-2 was discovered 
first with chromosomal translocation of t (14; 18), which occurs in the 
majority of indolent B-cell non-Hodgkin lymphomas, it has been associated 
with many other aggressive tumor phenotypes such as melanoma, 
lymphoma, lung, colon, prostate cancers and breast cancer
81- 84
.  
G3139 has been shown to effectively reduce both Bcl-2 mRNA and 
protein expression and enhances the chemotherapeutic effects of a broad 
range of chemotherapy agents, including chemotherapy, radiation, 
monoclonal antibodies and immunotherapy in preclinical studies
85-91
. G3139 
has been in clinical trials since 1995 in the U.S.A., Europe and Australia, 
with efficacy and safety data from phase 1, phase 2 and phase 3 clinical 
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trials. G3139 is now being evaluated clinically in the treatment of 
melanoma, chronic lymphocytic leukemia, lymphoma, acute myelogenous 
leukemia, advanced merkel cell carcinoma, lung, colon, prostate cancers and 
breast cancer as monotherapy or in combination with many types of 
anticancer therapies
82-84, 92-100
 
In this study, we used a cationic peptide amphiphile molecule, Lys-PA 
(C12-VVAGK-Am), as a non-viral antisense oligonucleotide carrier system. 
Positively charged carrier systems for oligonucleotide delivery have been 
used to provide effective cellular uptake through enhanced binding to 
negatively charged proteoglycans on the cell surface
101-102
. Besides, these 
peptide amphiphiles have good affinity to cell membranes since hydrophobic 
content of the PA molecules facilitates internalization through cell 
membrane lipids
103
. The hydrophilic lysine residues were chosen to bind to 
oligonucleotides and form nanofibers at physiological pH upon addition of 
oligonucleotides through charge screening. An amphiphilic peptide forming 
β-sheet structure with four non-polar amino acid residues and positively 
charged lysine residue at physiological conditions was designed and 
synthesized to interact with oligonucleotides. Poly-amine groups presented 
on the surface of the self-assembled nanofibers provide positive charge at 
physiological pH that can facilitate the uptake of Lys-PA - ODN 
complexes
104-105
. Oligonucleotides can be released by degradation of the 
biodegradable peptide scaffold or by physical release mechanisms governed 
by diffusion. Cells can uptake nanofibers degraded by proteases and use 
them in their metabolic pathways showing biocompatibility of PAs
106
.  
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RGDS-PA (C12-A3KKRGDS-Am) was the second peptide amphiphile in 
our study. This peptide amphiphile sequence is comprised of hydrophobic 
alkyl tail, three alanines and two lysines with RGDS (arginine-glycine-
aspartic acid- serine) residues. Unlike Lys-PA, bioactive RGDS sequences 
were also incorporated into the peptide segments to improve the 
internalization pathway and enhance targeting cellular uptake 
through receptor-mediated endocytosis
107
. Three-alanine sequence and 
positively charged two lysine residues at physiological conditions were 
designed and synthesized to form β-sheet structure and interact with 
oligonucleotides, respectively.  
Controlled release of ODN from Lys-PA - ODN system, ODN 
internalization by cells and effects of this nano-carrier system on Bcl-2 
mRNA levels are demonstrated. We showed that Lys-PA and ODN 
molecules form nanofibers through charge screening by using circular 
dichroism, SEM and AFM imaging. Lys-PAs undergo self assembly with 
addition of ODN to form dynamic nanostructure and affinity of ODN to 
Lys-PA analyzed with FRAP experiment. We showed that Lys-PA - ODN 
assembly provides controlled release of ODN from peptide nanofibers, 
enhanced intracellular accumulation of ODN and downregulation of Bcl-2 
mRNA.  We also showed that incorporation of bioactive RGDS sequence to 
the peptide increased cellular uptake of ODN.  
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Figure 2. Mechanism of action for Genasense®. Reproduced with permission 
from Genta Inc., NJ 
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EXPERIMENTAL SECTION 
 
2.1.  Materials 
 9-Fluorenylmethoxycarbonyl (Fmoc) and tert-butoxycarbonyl (Boc) 
protected amino acids, [4-[α-(2',4'-dimethoxyphenyl)Fmoc-
aminomethyl]phenoxy]acetamidonorleucyl-MBHA resin (Rink amide 
MBHA resin) and 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) were purchased from NovaBiochem and 
ABCR. DMEM media, fetal bovine serum (FBS), trypsin EDTA and 
penicillin streptomycin were purchased from Invitrogen.  
2.2. Antisense Oligonucleotides 
G3139, a phosphorothioate oligodeoxynucleotide (Genasense
®
), with a 
sequence complementary for the first six codons of the open reading frame 
of Bcl-2 mRNA: 5′-tct ccc agc gtg cgc cat-3′ (18-mer) was used as the 
antisense ODN. A two-base mismatched (MM) sequence, G4126, 5′-tct ccc 
agc atg tgc cat-3′, was used as control and G3139 labeled with 6-fluorescein 
on the 5‟-t, G4243, 5′-tac cgc gtg cga ccc tct-3′, was used in cell 
internalization assays. ODNs were donated by Genta Inc. (Genta Inc., NJ). 
15 
 
2.3. Cells 
The human breast cancer cell line MCF-7 (American Type Culture 
Collection) was maintained in DMEM low glucose (GIBCO) supplemented 
with 10% FBS, 100 µg/ml streptomycin and 100 µg/ml penicillin at 37 °C in 
a humidified incubator with 5% CO2.  
2.4. Peptide Synthesis, Purification and Characterization  
2.4.1. Synthesis of Peptide Amphiphiles 
Lauryl-VVAGK and Lauryl-AAAKKRGDS peptides were constructed 
on MBHA Rink Amide resin. Amino acid couplings were done with 2 
equivalents of Fmoc protected amino acid, 1.95 equivalents of HBTU and 3 
equivalents of DIEA for 2 h. Fmoc removal was performed with 20% 
piperidine/dimethylformamide (DMF) solution for 20 min. Cleavage of the 
peptides from the resin was carried out with a mixture of TFA: TIS: H2O in 
ratio of 95:2.5:2.5 for 3 h. Excess TFA was removed by rotary evaporation. 
The remaining viscous peptide solution was triturated with ice-cold ether 
and the resulting white product was freeze-dried. Peptide was characterized 
by liquid chromatography-mass spectrometry (LC-MS). Mass spectrum was 
obtained with Agilent LC-MS equipped with Zorbax SB-C8 4.6 mm x 100 
mm column. A gradient of (a) water (0.1% formic acid) and (b) acetonitrile 
(0.1% formic acid) was used for LC-MS characterization. Peptide 
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purification was performed with a Zorbax prepHT 300SB-C8 column with 
water-acetonitrile (0.1% TFA) gradient. 
2.4.2. Characterization of Peptide Amphiphiles 
 Circular Dichroism (CD) Spectra Measurement  
JASCO J815 CD spectrapolarimeter was used at RT to analyze 
secondary structures in 400 µl of peptide solution alone at a final 
concentration of 3.8 x 10
-4
 M of Lys-PA at pH 7 or 0.09 x 10
-4
 M of RGDS-
PA at pH 10 or pH 6 and mixture of Lys-PA (3.8 x 10
-4
 M final) and ODN 
(3.125 µM final) solution or RGDS-PA (0.09 x 10-4 M final) and ODN (1 
µM final) solution at wavelengths ranging from 260 nm to 190 nm, data 
interval and data pitch being 0.1 nm, scanning speed being 100 nm/min. All 
measurements were done with three accumulations. D.I.T. was selected as 1 
sec, band width as 1 mm, and the sensitivity was standard. 
Viscoelasticity and Gelation Behavior  
 Gelation behaviors of the ODN and Lys-PA gels were evaluated by an 
Anton Paar Physica RM301 Rheometer operating with a 25 mm parallel 
plate configuration at 25 °C. Each sample with 100 µL of total volume with 
a final peptide concentration of 1 wt% and ODN solutions with different 
concentrations was carefully loaded on the center of the lower plate and 
incubated for 15 min before performing rheometry analysis. After 
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equilibration, the upper plate was lowered to a gap distance of 0.5 mm. 
Storage moduli (G′) and loss moduli (G″) values were measured from 100 
rad/s to 0.1 rad/s of angular frequency with 0.5% shear strain. 
Morphological Observation 
Three-dimensional network of the nanofibrous gel was observed by 
atomic force microscopy (AFM) and scanning electron microscopy (SEM).  
Atomic Force Microscopy (AFM)  
AFM sample was prepared by mixing 0.02 wt % Lys-PA or 1 wt % 
RGDS-PA and ODN solutions in ddH2O. After incubation for 30 min at RT, 
mixture of Lys-PA and ODN was diluted 20 times in H2O or mixture of 
RGDS-PA and ODN was diluted 100 times to obtain 0.5 µM ODN 
concentration. Final solution was drop-casted and dried on a freshly cleaved 
silicon wafer. AFM images were recorded using model MFP-30 from 
Asylum Research operated in tapping mode at a frequency of 246 kHz. AFM 
images were taken at 1024×512 pixels resolution. Image was taken with 
spring constant 40 N/m and the set point and scanning speed were 0.7–1.0 V 
and 1.0–1.5 Hz, respectively. 
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Scanning Electron Microscopy (SEM)  
3-D network of self-assembled 100 μl gels prepared on a metal mesh by 
mixing 50 μl of 1 wt% PA solution in H2O with 50 μl of  ODN solution in 
PBS (1X, pH 7.4) containing 250 ng/µl of ODN. Water was exchanged with 
ethanol gradually in water/ethanol mixtures of increasing ethanol 
concentrations and finally in 100% ethanol for 30 sec at each step. Gel was 
dried at critical point (1072 psi, 31 ºC) with Tousimis Autosamdri-815B, 
Series C critical point dryer and coated with 10 nm Au-Pd. Sample was 
imaged by a FEI Quanta 200 FEG, using the ETD detector at high vacuum 
mode at a voltage of 30 keV 
2.5. ODN Release from PA-ODN Gel 
ODN release from PA-ODN gel was examined by diluting Lys-PA with 
H2O to 2 wt% in 50 µl and mixing with 50 µl ODN solution (30 µg/µl and 2 
µg/µl) in PBS (1X, GIBCO) to obtain a final 1 wt% peptide gel and 15 µg/µl 
ODN in the gel. After 15 min incubation, 100 µL of 1X PBS was added onto 
gel. Release of ODN was measured by NanoDrop (The Thermo Scientific 
NanoDrop 2000, USA) at 260 nm as initial release and measurements were 
continued for a period of 6 days for gel formed with 30 µg/µl ODN and 3 
days for gel formed with 2 µg/µl ODN solution. To examine the effect of PA 
and ODN concentration on release profile of ODN; 100 µl of gels were 
formed using ODN with concentrations of 150-1200 ng/µl and PA with 
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concentrations of 0.2-0.1 wt%. The gels were prepared in 96 well-plates and 
incubated for 1 h at 37 ºC followed by overnight drying in a laminar flow 
hood. Next day, 100 µl of PBS (1X) was added on coated wells and gels 
were maintained at 37 ºC for a period of 5 days during ODN concentration 
analysis. To see burst release, 2 µl aliquots from PBS solution were 
measured in short time intervals in the first day and every 24 h afterwards. 2 
µl of fresh buffer was added to wells after each measurement for all 
experiments. ODN release versus time was graphed according to initial 
concentration of ODN trapped in the gel. Three replicates were tested for 
each PA and ODN formulation.   
2.6.  Confocal Fluorescence Recovery after Photobleaching of 
FAM-Labeled ODN in PA-ODN nanofibrous network 
For photobleaching experiments, ﬂuorescent gels were obtained by 
mixing 10 µL of 0.1 wt % peptide amphiphile solution and 10 µL of 1000 
ng/µL oligonucleotide solution (97%  ODN and 3% FAM-ODN) after 10 
min incubation at RT.  Fluorescence images of the samples were acquired 
using the laser scan confocal microscope (ZEISS LSM 510 META, ZEISS 
GmbH, Jena, Germany) with a 63×, 1.2 NA oil-immersion objective using 
the 488 nm line of an argon laser and the 500–530 nm band pass filter at a 
512 pixel × 512 pixel resolution, at a scan speed of 9 and using a 95 μm 
pinhole.  FRAP experiments were carried out by scanning a square region of 
interest (ROI) and bleaching a circular ROI by exposing to 100 % 488 nm 
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light. Recovery of ﬂuorescence in this area and unbleached area was 
obtained by a time series using a low laser intensity of 0.5 % 488 nm light.  
2.7. In Vitro Studies  
2.7.1. Cellular Uptake of PA-ODN Complexes 
MCF-7 breast cancer cells (3×104 cells/ well) were plated in 0.5 ml of 
growth medium on coverslips in 24-well chambered plates and grown 
overnight. On the following day, the cells were treated with 20 µl of mixture 
with an equal volume of Lys-PA and FAM-labeled ODN (G3139) or 10 µl 
of FAM labeled ODN alone for 4 h. Mixture of 0.01 wt% Lys-PA and  FAM 
labeled ODN (30 ng/µl) in PBS and or FAM labeled ODN (120 ng/µl) in 
PBS and 1 wt% RGDS-PA in H2O was prepared by gently mixing ODNs 
and PAs, followed by incubation for 30 min at RT. After 4 h incubation, 
cells were rinsed three times with PBS, fixed with 4% paraformaldehyde and 
stained with 1 µg/ml solution of TO-PRO-3 (Invitrogen) for nuclei staining. 
In order to see distribution of PA-ODN complex in cell cytoplasm, after 4 h 
incubation with FAM labeled ODN alone and in PA-ODN mixture, cell 
culture medium was removed, 500 μl/well fresh cell culture medium was 
added and cells were incubated for an additional 44 h. Cells were imaged by 
a laser scan confocal microscope (ZEISS LSM 510 META, ZEISS GmbH, 
Jena, Germany). 
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2.7.2. Cell Viability and Proliferation Assay  
The cytotoxicity of the ODN, PA and PA-ODN complexes was 
measured by MTT [3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide] assay (Sigma). The MCF-7 cells were plated on 96- well plates at a 
density of 3000 cells/well and grown overnight. Next day, the cells were 
treated with either a 5 µl mixture of equal volumes of Lys-PA (0.02 wt%) 
and ODN/MM-ODN or a 2.5 µL solution of ODN/MM-ODN alone with 
final concentration of 1 µM .The cells were treated with either a 5 µl mixture 
of equal volumes of RGDS-PA (1 wt %) and ODN/MM-ODN or a 2.5 µL 
solution of ODN/MM-ODN alone with final concentration of 1 µM. After 
incubation at 37 °C for 4 h, cell culture medium was replaced with fresh 
medium followed by additional 44 h incubation.MTT assay was performed 
according to the manufacturer's protocol. Briefly, media on cells were 
aspirated and 100 µl fresh media containing 10% (v/v) reconstituted MTT 
(M-5655) reagent was added to each well. The plates were incubated for 3 h 
and the absorbance of the medium was measured at 570 nm with plate reader 
(SpectraMax M5, Molecular Devices). The background absorbance of 
multiwell plates were also measured at 690 nm and subtracted from the 570 
nm measurement.  
To confirm the effect of PA-ODN complex on proliferation of MCF-7 
cells, BrdU cell proliferation kit (Roche) was used. Cells were seeded at a 
density of 3000 cells/well in a final volume of 100 μl in 96-well culture 
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dishes and incubated overnight. The cells were treated with either a 5 µl 
mixture of equal volumes of Lys-PA (0.02 wt %) and ODN/MM-ODN or a 
2.5 µL solution of ODN/MM-ODN alone with final concentration of 1 µM . 
After incubation at 37 °C for 4 h, cell culture medium was replaced with 
fresh medium followed by additional 20 h incubation. . Next, 10 μl of 100 
µM BrdU label was added to each well and incubated for an additional 24 h 
at 37 °C. The labeling medium was removed by tapping off and replaced 
with 200 μl of fix/denaturing solution followed by 30 min incubation at RT. 
The fix/denaturing solution was removed thoroughly by flicking off and 
tapping. 100 µl/ well anti-BrdU-POD working solution was added to each 
well and left for 90 min at RT. Antibody conjugate was removed by flicking 
off and wells were rinsed 3 times with 200 -300 µl/well with washing 
solution (PBS, 1X). Finally 100 µl/well of substrate solution was added into 
wells and incubated at RT until color development is sufficient for 
photometric detection (30 min). Absorbance (A370 nm - A492 nm) of the 
samples was measured with plate reader (SpectraMax M5, Molecular 
Devices). Absorbance values were normalized with respect to cells 
incubated without ODN drug. Assays were carried out in triplicate. 
2.7.3. Determination of Bcl-2 mRNA Expression by Quantitative RT-PCR 
MCF-7 breast cancer cells were plated in 6-well plates containing 2 ml 
media. Following overnight growth at 37 ºC in a humidified incubator with 
5% CO2, cells were treated with either a 100 µl mixture of equal volumes of 
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Lys-PA (0.02 wt %) and ODN/MM-ODN or a 50 µL solution of ODN/MM-
ODN alone with final concentration of 1 µM. After incubation at 37 °C for 4 
h, cell culture medium was replaced with fresh medium followed by 
additional 44 h incubation.. The complexes of PA-ODN were prepared by 
mixing equal volumes of ODN solution in PBS (1X, GIBCO) and Lys-PA 
(0.02 wt %) in ddH2O and incubated for 30 min at RT before adding of this 
mixture onto cells. Total RNA was extracted from cells after 48 h and 72 h 
incubations by using Trizol reagent (Invitrogen). RNA concentration was 
measured with NanoDrop spectrophotometer (Thermo Scientific NanoDrop 
2000, USA) at 260 nm. 
The Bcl-2 mRNA expression level was measured by using quantitative 
RT-PCR with SuperScript™ III Platinum® SYBR® Green One-Step qRT-
PCR Kit (Invitrogen). Samples were incubated in C1000TM thermal cycler 
(CFX96
TM
 real Time systems, Bio-RAD). After cDNA synthesis for 3 min at 
50 ºC, cDNA denaturation was carried out for 5 min at 95 ºC followed by 
denaturation at 95 ºC for 15 sec and annealing at 60 ºC for 30 sec. Primer 
sequences were designed by using DNASTAR Lasergene 8 program. 
Following primer pairs were used for qRT-PCR experiments: 5‟tgc ccc tgt 
gga tga ctg ag‟3  and 5‟gtt tgg ggc agg cat gtt gac t‟3 for Bcl-2, 5‟tcg aca gtc 
agc cgc atc ttc t‟3 and 5‟gtg acc agg cgc cca ata cga c‟3 for GAPDH. 
Relative gene expression values were determined by the Pfaffl method. 
GAPDH was used as housekeeping gene to normalize the gene expression 
levels of each sample. 
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2.7.4. Western Analysis 
MCF-7 breast cancer cells were plated in 6 well plates containing 2 ml 
media. Following overnight growth at 37 °C in a humidified incubator with 
5% CO2, cells were treated with either a 100 µl mixture of equal volumes of 
Lys-PA (0.02 wt%) and ODN/MM-ODN or a 50 µL solution of ODN/MM-
ODN alone with final concentration of 1 µM . After incubation at 37°C for 4 
h, cell culture medium was replaced with fresh medium followed by 
additional 44h and 68 h incubation. The complexes of PA-ODN were 
prepared by mixing equal volumes of ODN solution in PBS (1X, GIBCO) 
and Lys-PA (0.02 wt %) in ddH2O and incubated for 30 min at RT before 
adding of this mixture onto cells. After 48 h and 72 h incubation, MCF-7 
cells were washed with 1X PBS and lyzed with 100 μl 1X SDS-sample 
buffer. The extract was transferred to a microcentrifuge tube and centrifuged 
at 13,000 x g for 10 min at 4 ºC. The supernatant was collected to a fresh 
tube and the total protein concentration was determined by using BCA 
protein assay (Pierce, Rockford, IL).  Cell lysates containing 50 μg of total 
protein were loaded and separated on a 10% SDS-polyacrylamide gel at 150 
V for 1.5 h. After blotting (trans-blot SD, Semi Dry transfer cell, Bio-Rad) 
to polyvinylidine difluoride membranes (Thermo Scientific) at 14 V for 35 
min, the membrane was blocked in a solution of 5% powdered nonfat milk 
in Tris-buffered saline/Tween-20 followed by incubation with monoclonal 
anti-Bcl-2 clone 100 (Millipore) (1:1000) or monoclonal Anti-β-Actin 
antibody (1:5000) (Sigma-Aldrich). After washing with milk, the 
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membranes were incubated with horseradish peroxidase conjugated goat 
anti-mouse secondary antibody (Millipore) (1:2000). The membranes were 
developed with Novex® Chemiluminescent Substrates-(Invitrogen) and 
observed with Kodak Biomax NS film.  
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RESULTS AND DISCUSSION 
 
3.1. Peptide Synthesis, Purification and Characterization  
Lauryl-VVAGK-Am (Lys-PA) (Fig. 4a) peptide was synthesized by 
utilizing solid phase peptide synthesis method (Fig. 3). The mass 
spectrometry and HPLC chromatogram are shown in Figures 4 and 5.  
Lauric acid provides amphiphilicity with its hydrophobic character that 
triggers peptide molecule to self assemble into nanofibers. The β-sheet 
forming group consists of four non-polar amino acid residues to form β-
sheet module. Lysine residue provides water solubility and a cationic feature 
which triggers self supporting gel formation upon mixing with negatively 
charged oligonucleotides (Fig. 4c) through self assembly process (Fig. 7).  
Secondary structures of the nanofibers formed through charge 
neutralization of the Lys-PA molecules by mixing with ODNs were 
analyzed by circular dichroism (CD). Circular dichroism examination of PA 
with ODN demonstrated that PA formed predominantly β-sheet structure at 
a concentration of 3.8 x 10
-4
 M in water. The typical β-sheets display a 
negative minimum at 218 nm and a positive ellipticity at 195 nm suggesting 
the b-sheet contents and b-sheet packing, respectively
108
. CD spectrum of 
PA without ODN at the same concentration revealed a mixture of random 
coil and β-sheet structures109. The amount of β-sheet structures in the PA 
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alone samples was much lower compared to CD spectrum of the PA with 
ODN (Fig. 8).  Characterization of PA-ODN solution by AFM and gel by 
SEM imaging revealed their 3-D nanofibrous network structure (Fig. 9a and 
b). Lys-PA, which is positively charged at acidic pH, can form gel through 
neutralization by making the pH basic or by addition of positively charged 
ODN at physiological pH. Lys-PAs self-assemble into nanofibers upon 
addition of oppositely charged ODN through charge screening and three 
dimensional network of these nanofibers results in gel formation upon water 
encapsulation. This observation suggests that nonporous structure can be 
used for controlled release of DNA based drugs and therapeutic proteins.  
Network formation is critical for drug release since it enables physical 
encapsulation of the drug in addition to electrostatic interactions between the 
ODN and PA molecules. In addition, ODN release is dependent on 
electrostatic interactions between the PAs and ODNs. Therefore, PA 
degradation can be responsible for additional ODN release in vitro and in 
vivo. Encapsulation of water by the 3-D nanofibrous network resulted in gel 
formation triggered by addition of ODN solution as demonstrated by 
oscillatory rheology. G‟ and G” did not change with angular frequency from 
100 rad/s to 0.1 rad/s (Fig. 10). As we increased the ODN amount, storage 
moduli (G‟) of samples increased and became significantly higher than their 
loss moduli (Fig. 11). G′/G′′ was higher than 1, a critical point of gelation, 
which indicates PA-ODN gel behaves like an elastic solid
54
.  
28 
 
 
Figure 3. Solid Phase Synthesis Diagram. Reproduced with permission from 
Sigma-Aldrich. 
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Figure 4. (a) Chemical representation of Lys-PA, (b) RGDS-PA and (c) 
Chemical structure of the backbone of the phosphorothioate G3139. 
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Figure 5. Mass spectrometry of the Lys-PA. 
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Figure 6. RP-HPLC chromatogram of the Lys-PA. 
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Figure 7. Schematic representation of the fibrous gel of Lys-PA (2 wt %) and 
Fluorescein tagged-ODN (1000 ng/µl) 
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Figure 8. CD spectra demonstrate increased β-sheet formation in PA- ODN 
mixture compared to PA alone 
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Figure 9. (a) AFM topography and (b) SEM images of nanofibrous 3-D network 
of the Lys-PA and ODN complex 
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Figure 10. Frequency sweep profiles of gels of Lys-PA (2 wt %) with ODN 
at different final concentrations (75-250 µM). Data points are average of n=3 
and error bars represent standard error of mean. 
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Figure 11. Storage modulus (G′) and loss modulus (G′′) of gels of Lys-
PA (2 wt %) with varying concentrations of ODN at angular frequency of 
100 rad/s. Data points are averages of n=3 and error bars represent standard 
error of mean 
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3.2.  ODN Release from PA-ODN Gel 
We evaluated the effect of the Lys-PA and ODN concentrations on the 
release of ODN through release assays. This system offers a distinctive 
advantage that self-assembly process is triggered with addition of ODN or 
any other desired drug that can be directly encapsulated into network 
compared to the loading of the drugs. The nanofibrous nature of the PA-
ODN system enables physical encapsulation of the ODN as well as 
increasing the physical interaction between the PA and ODN molecules. The 
release profile of ODN from gel prepared by mixing 50 µl of 2 wt% Lys-PA 
and 50 µl of 30 µg/µl ODN is shown in Figure 12a. We monitored sustained 
release of ODN from 3-D PA-ODN nanofibrous network while the majority 
of ODN (80–90%) was released by 6 days (Fig. 12a). Effect of charge ratio 
is an important factor that determines the strength of the electrostatic 
interactions and it was further studied by changing peptide concentration in 
the PA-ODN gels. For this purpose, ODN release was studied with a gel of 2 
µg/µl (2000 ng/µl) ODN and 2 wt% Lys-PA for 3 days (Fig. 12b). 
Representative image of PA-ODN gel is shown in Figure 12c. Release of 
ODN from gel formed with 30 µg/µl ODN solution was around 55% by day 
3 while release of ODN from gel formed with 2 µg/µl ODN was around 15% 
with a slower release profile. In addition, figure 13 demonstrates that ODN 
release from gel decreased as the peptide concentration was increased due to 
enhanced attraction of anionic ODNs by the cationic nanofibrous network. 
The average release profile was also affected by the concentration of ODN 
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in the gel, where higher the ODN concentration, higher the ODN release 
from gel due to insufficient attraction by cationic Lys-PAs on anionic ODNs 
in the gel. At low ODN concentrations (150 ng/µl in Fig. 13a and 300 ng/µl 
in Fig. 13b), 66% of the initial amount of ODN was trapped in the 0.1 and 
0.2 wt% Lys-PA-ODN gels and release from the 3-D network was slow for 
all three concentrations of PAs. Release assay from the gels with 600 ng/µl 
ODN concentration showed rapid initial release within the first 3 h when 0.1 
wt% gel was used where slower release profiles from 0.15 wt% and 0.2 wt% 
gels (Fig. 13c). When a higher concentration (1200 ng/µl) of ODN was used 
for release assays, rapid initial release within the first 3 h was observed for 
all three PA concentrations (Fig. 13d). After 2 days, release profile reached 
plateau values for all formulations. When same PA concentration was used 
for encapsulating different concentrations of ODN, using lower 
concentrations of ODN resulted in slower release while as ODN 
concentrations were increased, more rapid initial release profiles were 
observed. 
Antisense oligonucleotides are not only localized on the surface of the 
nanofibers by electrostatic interactions between positively charged PA 
molecules and negatively charged ODNs, but also physically encapsulated 
inside the peptide nanofiber network. The initial burst release is due to 
weaker interactions between the ODNs and the PAs which is caused by 
physical encapsulation. The latter slow release is likely to be caused by 
stronger bonds caused by electrostatic interactions between the PA and ODN 
molecules. Therefore, self-assembled PA and ODN nanofibers can be used 
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for controlled ODN release by changing PA/ODN charge ratio and the PA-
ODN nanofiber network provides a promising tool for controlled release of 
oligonucleotides. It is known that oligonucleotides have short half-lives in 
the body. Consequently, agent-free antisense ODN (G3139) is generally 
applied by continuous intravenous infusion. Thus, utilization of an effective 
delivery system is required to improve the efficacy of gene targeted therapy 
while providing elimination of side effects in the circulatory system after 
injection.  
The ﬂuorescein labeled ODN in the PA-ODN gel was photobleached in 
an area 173 µm2 and the recovery of ﬂuorescence was monitored over time 
in the same area and compared with fluorescein intensity of non-bleached 
area.  After photobleaching of fluorescein-ODN irreversibly, 
mobile/unbound fluorescent ODN or under dynamic assembly process, 
unbleached fluorescein-ODN molecules moved to the bleached area and 
caused recovery of the fluorescein. Recovery occurred almost after 8 
minutes suggesting that ODN has high affinity to PA (Fig. 14). Although 
determination of the diffusion constant of ODN in the PA network is 
difficult by FRAP experiment, affinity of different additives such as other 
peptides or macromolecules to peptide amphiphiles can be compared.  
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Figure 12. Release profile shows of ODN from peptide nanofiber (a) gel of 30 
µg/µl ODN and 2 wt % PA for 6 days, (b) gel of 0.2 µg/µl ODN and 2 wt % PA 
for 3 days. (c) Representative image of gel with PBS used for release 
experiments. Data points are average of n=3 and error bars represent standard 
error of mean. 
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Figure 13. Release profile of ODN from (a) gel of 0.1%, 0.15% and 0.2 wt% 
PA and ODN at concentrations of 150 ng/µl, (b) 300 ng/µl, (c) 600 ng/µl, and 
(d) 1200 ng/µl for 5 days. Data points are average of n=3 and error bars 
represent standard error of mean. 
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Figure 14. Intensity graph of area of fluorescein ODN area at time of pre-
bleach, post bleach and post-recovery compared to unbleached area 
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3.3.   In Vitro Studies 
Incorporating ODNs into self-assembled Lys-PA nanofibers also 
enhanced ODNs‟ in vitro activity and their cellular uptake. Intracellular 
distribution of PA-ODN complexes was examined by laser scan confocal 
microscopy (Fig. 15a). MCF-7 cells were incubated with FAM labeled PA-
ODN complex and free FAM labeled ODN for 4 h at 37°C followed by 
fixation. In order to see the distribution of PA-ODN complexes in cell 
cytoplasm over time, cells were treated with PA-ODN containing media for 
4 h, after which the medium was removed. Fresh cell culture medium was 
added and cells were incubated for an additional 44 h before fixation. After 
48 h, we observed that PA-ODN complexes were internalized by cells (Fig. 
15b). The internalization of ODN by cells is continuous and thus 
effectiveness of ODN is sustained. Stronger fluorescent intensity was 
observed in the cells treated with PA-ODN complex after both 4 h 
incubation and 48 h incubation with respect to the ODN alone, indicating 
enhanced cellular uptake of ODN when it is applied with positively charged 
PA due to their amphiphilic and cationic properties.  
In our case, ionic interactions of positively charged lysine residues with 
membrane-bound heparan sulfate proteoglycans (HSPGs) induce non-
specific uptake of complexes. The exact mechanism of cellular 
internalization of ODN with peptide amphiphile nanofibers remains unclear 
and will be studied. The most likely way of internalization can be 
macropinocytosis formed by actin-driven membrane ruffling, by which 
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positively charged complexes are endocytosed in fluid-filled vesicles. These 
vesicles may fuse with degradative late endosomes or bypass the lysosomal 
compartment and traffic directly to the nucleus
110-111
. The proposed 
mechanism is represented in Figure 16.   
In order to analyze the effects of Lys-PA - ODN complex on cell 
viability and proliferation, MTT viability and BrdU proliferation assays 
were carried out by using MCF-7 cells. Cells incubated with Lys-PA - ODN 
complex had lower viability than ODN alone, which proves that ODN is an 
effective delivery agent. Cells treated with Lys-PA - ODN complex also had 
lower viability compared to cells treated with Lys-PA - MM ODN complex, 
which shows that the decreased viability is not caused by the Lys-PA 
molecules. Proliferation assays revealed no significant differences between 
cells treated with ODN, MM-ODN, Lys-PA - ODN and Lys-PA - MM 
ODN. This result is consistent with previously published data
112
 (Fig. 17a 
and b).  
Functional delivery of ODN with Lys-PAs was also confirmed by real 
time PCR analysis, which revealed that Lys-PA and ODN (G3139) complex 
induced downregulation of the Bcl-2 mRNA. MCF-7 cells treated with PA-
ODN complex (G3139) exhibited a 70% downregulation in Bcl-2 mRNA 
levels when compared to treatment groups with Lys-PA - mismatch ODN 
(G4126), ODN (G3139) alone and mismatch ODN (G4126) alone when 4 h 
long treatment was applied to cells followed by 44 h of incubation without 
treatment (Fig. 18a). At 72 h, downregulation of Bcl-2 mRNA levels was 
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around 30% for cells treated with the Lys-PA - ODN complex, which was 
not significantly different than the other treatment groups (Fig. 18b). The 
increase in Bcl-2 mRNA levels at 72 h compared to 48 h might be caused by 
development of resistance by MCF-7 cells against ODN treatment, similar to 
previously published data
113
. All expression levels were normalized to cells 
without any ODN treatment. These findings suggest that PAs can effectively 
deliver ODNs for gene-targeted therapies.  
The effect of the Bcl-2 antisense ODN (G3139) and its two base 
mismatch control (G4126) as naked and with Lys-PA on Bcl-2 protein levels 
in MCF-7 cells were also examined with western blot analysis, however, 
Lys-PA - ODN complex did not reveal any significant differences in the Bcl-
2 protein levels compared to cells incubated with only cell culture medium. 
This result might be caused by the post-transcriptional and post-translational 
regulation mechanisms that are normally employed by cells to regulate 
protein levels and is a matter of effectiveness of G3139 itself which is also 
shown with QRT-PCR results. At 48 h (Fig. 19) and 72 h (Fig. 20), 
downregulation of Bcl-2 protein levels in cells treated with Lys-PA - ODN 
complex was not significantly different than the other treatment groups. 
Nevertheless, the reduction in Bcl-2 mRNA levels by itself at 48 h is 
sufficient to deduce that our delivery system enables effective delivery of the 
ODN agent. All in vitro experiments were carried out with serum containing 
media in which most of the ODN carrier systems do not work
42
. ODNs in 
the Lys-PA - ODN complexes are released by degradation of the 
biodegradable peptide scaffold. Synthesis and application of PAs as carrier 
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and delivery agents have advantage of convenience in usage over other 
biodegradable lipids and polymers. Moreover peptide amphiphile assembly 
occurs at physiological conditions spontaneously with addition of drug and 
injectable through small needles while polymers need addition of catalysts 
or material processing for the supramolecular self-assembly and reassembly 
event. Due to their biocompatibility, bioactive sequences and highly ordered 
nanostructures, PA nanofibers are promising drug and gene delivery 
systems. 
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Figure 15. Representative images of MCF-7 cells treated with (a) naked FAM 
labeled ODN (green); (b) FAM labeled ODN and 0.01 wt% PA complex for 4 h 
followed by an additional incubation of 44 h without treatment at 37 
o
C. TO-
PRO-3
®
 (blue) was used to stain the nuclei. Images were taken at 63X 
magnification 
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Figure 16. The proposed mechanism of PA – ODN complex (adapted 
from with permission from Leong et. al.)
111
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 Figure 17. (a) Viability and (b) proliferation assay results of MCF-7 cell line 
incubated with naked ODN/MM (mismatch) and complex with Lys-PA. Data 
points are averages of n=3 and error bars represent standard error of mean. 
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Figure 18.  Change in gene expression of Bcl-2 in MCF-7 breast cancer cells 
incubated with PA-ODN (G3139)/mismatch (G4126) complexes and free 
ODN/mismatch. Total RNA was extracted from cells after 4 h of treatment 
followed by (a) 44 h (b) 68 h of incubation without treatment. GAPDH was used 
as housekeeping gene to normalize the gene expression level using Pfaffl 
method. Data points are averages of n=3 and error bars represent standard error 
of mean. 
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Figure 19. Western blot analysis of Bcl-2 protein expression in MCF-7 cells 
incubated for 48 h with Lys-PA - ODN complex.  
 
 
 
 
 
 
 
Figure 20. Western blot analysis of Bcl-2 protein expression in MCF-7 cells 
incubated for 72 h with Lys-PA - ODN complex. 
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3.4.  Future Perspectives 
Lauryl-AAAKKRGDS-Am (RGDS-PA) (Fig. 4b) peptide was 
synthesized by solid phase peptide synthesis method (Fig. 3). The mass 
spectrometry and HPLC chromatogram of the molecule are shown in 
Figures 21 and 22.  Lauric acid provides amphiphilicity with its hydrophobic 
character that triggers peptide molecules to self assemble into spherical 
aggregations in water (Fig. 23).  Nonpolar amino acid residues of three 
alanine amino acids were used to form the β-sheet as secondary structure. 
However, CD spectra revealed that when RGDS-PA was mixed with ODN, 
random coil formation was the main aggregation form (Fig. 24). Due to the 
neutralization of head groups by electrolytes, the CD spectrum of the 
RGDS-PA solution at pH 10 shows the same tendency with RGDS-PA 
solution mixed with negatively charged ODN solution. In Figure 24, CD 
spectra of RGDS-PA at pH 10 and in mixture of ODN reveal random coil 
conformation with a negative minimum at 195 nm and a positive ellipticity 
at 212 nm
109
. On the other hand at pH 6, this PA did not display the typical 
random coil conformation that was evidence of a more unstable structure 
than the former. High pH causes neutralization of charges of head group and 
addition of ODN causes reduced hydrophilic head group repulsion. These 
result in formation of more compact RGDS-PA with spherical structures 
under charge screening. Furthermore, characterization of mixture of RGDS-
PA with ODN by AFM imaging revealed that the RGDS-PAs aggregate in 
spherical form but not in nanofibers (Fig. 25). We used three alanine 
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residues to induce β-sheet formation; however these residues and 
hydrophobic interaction between alkyl tails were not enough to overcome 
the electrostatic repulsion between head groups to form nanofibers with high 
packing. Self-supporting gel formation was not observed even at high 
concentration of ODN solution. Studies on this PA are going on to obtain 
more stable mono-dispersed nanostructure with higher transfection 
efficiency for gene delivery. 
Unlike Lys-PA, bioactive RGDS sequence was incorporated into the 
peptide to improve the uptake of ODN by MCF-7 cells through receptor-
mediated endocytosis. Highly expressed integrins on the surface of cancer 
cells interact with RGDS sequence, which enables us to use this sequence as 
targeting agent and to induce endocytosis process.  Intracellular distribution 
of RGDS-PA - ODN complexes was examined by laser scan confocal 
microscopy. MCF-7 cells were incubated with FAM labeled PA-ODN 
complex and free FAM labeled ODN for 4 h at 37 °C followed by fixation. 
After 4 h incubation, RGDS-PA - ODN complexes were mostly localized at 
cell surface (Fig. 26a). In order to see distribution of RGDS-PA - ODN 
complexes in cell cytoplasm over time, cells were treated with RGDS-PA - 
ODN including media for 4 h, after which medium was removed. Fresh cell 
culture medium was added and cells were incubated for an additional 44 h 
before fixation. After 48 h, we observed that PA-ODN complexes were 
internalized by cells and shows fluorescent structures such as endosome 
compartments (Fig. 26b).  Stronger fluorescent intensity was observed in the 
cells treated with PA-ODN complex after both 4 h incubation and 48 h 
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incubation with respect to ODN alone.  Further functionalization with a cell-
adhesion motif RGDS sequence that specifically binds to integrins enhanced 
cellular uptake of ODN.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Mass spectrometry of the RGDS-PA. 
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Figure 22. RP-HPLC chromatogram of the RGDS-PA. 
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Figure 23. Schematic representation of the RGDS-PA (0.04 wt %) and 
Fluorescein tagged-ODN (200 ng/µl) complexes 
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Figure 24. CD spectra of RGDS-PA and ODN mixture compared to PA alone at 
pH 6 and pH 10.  
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Figure 25. AFM topography images of the RGDS-PA and ODN complexes 
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Figure 26. Representative images of MCF-7 cells treated with (a) naked 
FAM labeled ODN (green); (b) FAM labeled ODN and 1 wt % RGDS-
PA complex for 4 h followed by an additional incubation of 44 h without 
treatment at 37 
o
C. TO-PRO-3
®
 (blue) was used to stain the nuclei. 
Images were taken at 63X magnification 
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CONCLUSION 
Development of carrier systems for controlled ODN release and efficient 
cellular uptake of ODNs is crucial for gene targeted therapy. In this study, 
we developed a novel carrier system consisting of peptide amphiphiles and 
antisense oligonucleotides and analyzed the efficiency of controlled ODN 
release and delivery. The cationic Lys-PA molecule self assembled upon 
addition of ODN and formed nanofibrous network in which oligonucleotides 
bind to peptide nanofibers through electrostatic interactions and form a 
stable complex. Our results demonstrate that ODN release profile depends 
on concentrations of the peptide amphiphile and ODN in the gel due to 
electrostatic attractions between cationic and anionic groups. 3-D nanofiber 
network is also effective in encapsulation and release of ODN in a sustained 
manner. PA-ODN nanofibers delivered ODN efficiently and enhanced 
cellular uptake by MCF-7 cells, which resulted in downregulation of Bcl-2 
mRNA levels. Cationic Lys-PA could be a tool for slow release and delivery 
of ODNs for gene targeted therapy. By combining apoptotic therapeutics and 
ODN treatment, PA nanofibers provide a promising tool for cancer treatment 
through loading peptide amphiphile gel with several drugs with different 
mechanisms of action to enhance apoptotic activity. 
Peptide amphiphile system can be also used for delivery of other type of 
antisense agents such as siRNA and splice-correcting phosphorothioate 
RNA antisense. PA nanofibrous system offers site-specific delivery of 
oligonucleotides by injectable gels applied to treatment site. Compared to 
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intravenous administration, site specific delivery is expected to cause fewer 
side effects. In addition, this practical system can reduce the number of drug 
administrations, which cause patient discomfort and might lead to infections. 
Because of their hydrophobic and hydrophilic properties, both hydrophobic 
and hydrophilic drugs can be loaded into gel by self assembly process and 
sustainable and controlled release of these drugs can be obtained.  To our 
knowledge, ODN integrated into the nanofiber network of PA has not been 
report for delivery. This system can be improved with incorporation of bio-
active peptide sequence such as RGDS sequences to increase delivery 
efficiency and in vitro studies are continuing.  
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